Integrin alpha V

Integrin alpha-V is a protein that in humans is encoded by the ITGAV gene.[5]

ITGAV
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesITGAV, CD51, MSK8, VNRA, VTNR, integrin subunit alpha V
External IDsOMIM: 193210 MGI: 96608 HomoloGene: 20510 GeneCards: ITGAV
Orthologs
SpeciesHumanMouse
Entrez

3685

16410

Ensembl

ENSG00000138448

ENSMUSG00000027087

UniProt

P06756

P43406

RefSeq (mRNA)

NM_001144999
NM_001145000
NM_002210

NM_008402
NM_001398691

RefSeq (protein)

NP_001138471
NP_001138472
NP_002201

NP_032428
NP_001385620

Location (UCSC)Chr 2: 186.59 – 186.68 MbChr 2: 83.55 – 83.64 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

ITGAV encodes integrin alpha chain V. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. Alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Among the known associating beta chains (beta chains 1,3,5,6, and 8; 'ITGB1', 'ITGB3', 'ITGB5', 'ITGB6', and 'ITGB8'), each can interact with extracellular matrix ligands; the alpha V beta 3 integrin, perhaps the most studied of these, is referred to as the Vitronectin receptor (VNR). In addition to adhesion, many integrins are known to facilitate signal transduction.[6]

Alpha V class integrins

In mammals the integrins that include alpha-V are :

NameSynonymsDistributionLigands
αVβ1neurological tumorsvitronectin; fibrinogen
αVβ3vitronectin receptor[7]activated endothelial cells, melanoma, glioblastomavitronectin,[7] fibronectin, fibrinogen, osteopontin, Cyr61
αVβ5widespread, esp. fibroblasts, epithelial cellsvitronectin and adenovirus
αVβ6proliferating epithelia, esp. lung and mammary glandfibronectin; TGFβ1+3
αVβ8neural tissue; peripheral nervefibronectin; TGFβ1+3

Clinical significance

Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer,[8] and prostate cancer.[9]

As a drug target

The mAbs intetumumab, and abituzumab target this protein which is found on some tumour cells.[10]

See also

References

  1. GRCh38: Ensembl release 89: ENSG00000138448 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000027087 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Sosnoski DM, Emanuel BS, Hawkins AL, van Tuinen P, Ledbetter DH, Nussbaum RL, Kaos FT, Schwartz E, Phillips D, Bennett JS (June 1988). "Chromosomal localization of the genes for the vitronectin and fibronectin receptors alpha subunits and for platelet glycoproteins IIb and IIIa". The Journal of Clinical Investigation. 81 (6): 1993–8. doi:10.1172/JCI113548. PMC 442653. PMID 2454952.
  6. "Entrez Gene: ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)".
  7. Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D, Caspary RG, Lindberg FP, Armitage R, Maliszewski C, Delespesse G, Sarfati M (February 1999). "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23". The Journal of Cell Biology. 144 (4): 767–75. doi:10.1083/jcb.144.4.767. PMC 2132927. PMID 10037797.
  8. Waisberg J, De Souza VL, Affonso Junior RJ, Silva SR, Denadai MV, Margeotto FB, De Souza CS, Matos D (2014). "Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer". Anticancer Res. 34 (10): 5599–607. PMID 25275062.
  9. Cooper CR, Chay CH, Pienta KJ (2002). "The role of alpha(v)beta(3) in prostate cancer progression". Neoplasia. 4 (3): 191–4. doi:10.1038/sj.neo.7900224. PMC 1531692. PMID 11988838.
  10. Élez E, Kocáková I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J (January 2015). "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial". Annals of Oncology. 26 (1): 132–40. doi:10.1093/annonc/mdu474. PMID 25319061.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.